Product information
Bioport TriCombo is an intra-articular injection of N-acetylglucosamine (NAG), chondroitin sulfate and sodium hyaluronate in one pre-filled syringe. The values on this page are transcribed from the manufacturer’s brochure; the instructions for use govern.
Composition
A sterile, viscoelastic solution for intra-articular injection containing N-acetylglucosamine (30 mg/ml), chondroitin sodium sulfate (30 mg/ml) and sodium hyaluronate (16 mg/ml, 3 MDa) in a 2.25 ml pre-filled glass syringe. The hyaluronate and chondroitin sulfate are physically associated through hydrogen bonding; the product is not chemically or irradiation cross-linked.1
| Property | Value |
|---|---|
| Composition | Sodium hyaluronate, chondroitin sulfate, N-acetylglucosamine1 |
| Content per 2.25 ml syringe | 36 mg sodium hyaluronate, 67.5 mg chondroitin sodium sulfate, 67.5 mg N-acetylglucosamine1 |
| Concentration | 1.6% / 3% / 3%1 |
| Average molecular weight (hyaluronate) | 3 MDa1 |
| Elastic modulus G′ (0.5 Hz at rest / 2.5 Hz running) | 250 Pa / 490 Pa1 |
| Viscous modulus G″ (at rest / running) | 190 Pa / 275 Pa1 |
| Administration | 1 syringe at 6 months1 |
| Presentation | Pre-filled single-use glass syringe (Becton Dickinson), 2.25 ml1 |
The three ingredients
Chondroitin sulfate and hyaluronate are glycosaminoglycans (GAGs); N-acetylglucosamine is a precursor in their synthesis. Hyaluronic acid is the lubricating component. The descriptions below are the manufacturer’s.1
All three are components of the extracellular matrix of articular cartilage and synovial fluid, alongside collagen. The manufacturer describes glucosamine as essential for the formation of hyaluronic acid, chondroitin sulfate and keratan sulfate, and positions the formulation as supplementing the synovial fluid with components of that matrix.1
30 mg/ml (3%) · 67.5 mg per syringe
N-acetylglucosamine is a precursor in glycosaminoglycan synthesis. The manufacturer describes it as reducing cartilage degeneration and supporting regenerative processes, and as a structural component of articular cartilage and synovial fluid.1
30 mg/ml (3%) · 67.5 mg per syringe
A sulfated glycosaminoglycan. The manufacturer describes it as protecting cartilage and reducing inflammatory activity in the osteoarthritic joint, and as the natural cross-linking agent for the hyaluronate chains, bound in a 1:1 ratio.1
16 mg/ml (1.6%) · 36 mg per syringe
High-molecular-weight (3 MDa) sodium hyaluronate, not chemically or irradiation cross-linked. The manufacturer describes physical self-association with chondroitin sulfate through hydrogen bonds and hydrophobic interactions, forming a stable complex in aqueous solution.1
Rheology
G′ is the elastic (storage) modulus, the solid-like part of the response, and G″ is the viscous (loss) modulus, the fluid-like part; the brochure reports both at 0.5 Hz, which it labels at rest, and 2.5 Hz, which it labels running.1
Physical cross-linking
The manufacturer describes the hyaluronate and chondroitin sulfate as physically associated through hydrogen bonds and hydrophobic interactions, forming a complex in solution. No chemical or irradiation cross-linking is used.1
The manufacturer states that this association gives the solution stability and resistance to degradation by hyaluronidase, and that the absence of chemical or irradiation cross-linking is intended to reduce reactions after administration.1
Indication
The manufacturer’s brochure states the indication as: ‘As a viscoelastic supplement or as a replacement for the synovial fluid in the knee joint’ and ‘For the symptomatic treatment of mild to severe knee osteoarthritis’.1
Intended effects
The manufacturer describes the intended effects as pain relief, lubrication and mechanical support, and protection and regeneration of the cartilage. These are the manufacturer’s statements; individual results vary.1
Administration and schedule
TriCombo is for intra-articular injection by a physician. One syringe per treatment. The manufacturer recommends two treatment cycles per year, at six-month intervals.1
The brochure does not specify a technique beyond intra-articular injection. Approach and any use of image guidance are the treating clinician’s decision.1
Contraindications and warnings
This website does not summarise contraindications. Current instructions for use remain authoritative.2
Manufacturer
Manufacturer information